The company also received a notice from the US Patent and Trademark Office that it intends to grant a patent with claims covering certain methods for treating multidrug-resistant tumors or inhibiting metastasis with various pharmaceutical compounds, including indibulin.
Indibulin is an oral novel tubulin targeted agent. The drug is currently being evaluated in several Phase I and Phase I/II studies, both as a single agent and in combination with Tarceva and Xeloda, for the treatment of a variety of solid tumors.
Jonathan Lewis, CEO and chief medical officer of Ziopharm, said: “These patent notices of allowance extend our already substantial intellectual property portfolio for indibulin.”